Kakaku.com Shares Rise as Bain Capital and LY Corp Prepare Higher Takeover Bid Than EQT 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Japan Targets 1%+ Real Economic Growth With ¥370 Trillion Investment Plan 
White House Seeks $87.6 Billion Emergency Funding for Iran War, Farmers, and Ebola Response 
UBS Raises TSMC Price Target to T$3,400 on Strong AI Chip Demand Outlook 
Lenovo Shares Slide as AI-Driven Memory Demand Signals Higher DRAM and NAND Prices 
China Expands Export Controls, Adds 20 Japanese Companies to Restricted List 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Firmus Partners With Nvidia to Deliver 170,000 AI GPUs in $30 Billion Cloud Infrastructure Deal 
Morgan Stanley Raises Tesla Q2 Delivery Forecast on Strong Europe and China Demand 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
Japan Signals Preference for Low Interest Rates as BOJ Policy Debate Intensifies 
Momenta Launches Hong Kong IPO to Raise Up to $751 Million for AI and Robotaxi Expansion 
China Factory PMI Seen Returning to Growth in June as AI Export Demand Supports Economy 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Iran Attack in Strait of Hormuz Pushes Oil Prices Higher 
US Stock Futures Rise as US-Iran Ceasefire Hopes Boost Market Sentiment 
SK Plasma Co. Ltd. is building a new blood product plant with an investment of KRW300 billion or about $250 million. The facility is set to be constructed in Indonesia.
Once in full operation, the new plant is expected to have the capacity to produce one million liters of blood products per year. SK Plasma will break ground some time this year, and the plant will be completed in two years.
Business insiders revealed earlier this week that the South Korean firm that produces albumin, immunoglobulin, coagulation factors, and antithrombin received the final approval for the construction of its plant from the Ministry of Health and Welfare of Indonesia not long ago. The facility will process the collected blood plasma and turn them into therapeutic agents.
Business Korea reported that for this project, SK Plasma would partner with Infion through a joint venture (JV) agreement. It is an Indonesian pharmaceutical company that will SK Plasma with its business operation in the country.
The size of the company’s upcoming plant in Indonesia is said to have a bigger production capacity than its facility in Andong, South Korea. It will offer 1.6 times more than the 600,000-liter capacity of its Korean plant.
In any case, the new factory will produce six types of blood products like Liv Gamma and albumin. The Korea Herald reported that albumin and immune globulin, which will be produced at the SK Plasma Indonesian facility, are typically used for patients with hemophilia and immunodeficiency diseases. These are made through strict and rigorous processes, including the centrifugation of blood collected from blood donation drives.
The blood products will ensure a stable supply in Indonesia, where the population is already close to 300 million. It was said that 100% of the citizens are currently dependent on imports of blood products.
“By transferring technologies relating to blood products and installing a manufacturing facility in a country that has no related infrastructure, SK Plasma seeks to create new business opportunities and reach the company’s ESG goals,” Kim Seung Joo, SK Plasma’s chief executive officer, said in a statement.
